Bio-Rad Laboratories vs Bio-Techne Corporation
Bio-Techne holds the stronger position because it faces lighter direct competitive pressure than Bio-Rad while still growing revenue, whereas Bio-Rad is losing ground in chromatography and diagnostics to bigger rivals.
Bio-Rad Laboratories
Maker of lab instruments and reagents for gene research and clinical diagnostics testing
Bio-Techne Corporation
Maker of antibodies, proteins, and reagent kits for life science research and diagnostics labs
Dimension by dimension
| Dimension | Bio-Rad Laboratories | Bio-Techne Corporation |
|---|---|---|
| Pressure from rivals | Bio-Rad faces heavier direct pressure than Bio-Techne, with Thermo Fisher and Danaher taking share in diagnostics and chromatography, and process chromatography revenue down 13% currency-neutral. | Bio-Techne faces lighter competitive pressure, with pricing pressure coming mainly from lower-cost reagent makers Sino Biological and ACROBiosystems. |
| Recent revenue trend | Bio-Rad's Q1 2026 net sales grew 1.1% reported but fell 4.2% currency-neutral, and Clinical Diagnostics brought in $364 million. | Bio-Techne grew FY2025 net sales 5% organically to $1.2 billion, though Q3 FY2026 organic revenue dipped 2% amid softer biotech spending. |
| Underlying strength of the business | Bio-Rad shows narrower separation from competitors, consistent with its share losses in chromatography and diagnostics noted above. | Bio-Techne shows stronger underlying business separation, supported by a Protein Sciences segment operating margin of 42.6%. |
| Exposure to AI absorbing the product | Bio-Rad's instruments and reagents are rated unlikely to be absorbed by AI. | Bio-Techne's antibodies, proteins and diagnostic instruments are also rated unlikely to be absorbed by AI. |
| How easily a giant could copy them | A larger player copying Bio-Rad's offerings is rated possible. | A larger player copying Bio-Techne's offerings is also rated possible. |
| Ownership and financial backing | Bio-Rad reported FY2025 revenue of $2.58 billion as an independent company. | Bio-Techne is being acquired by Merck KGaA at $73.00 per share, valuing it at roughly $11.3 billion enterprise value. |
Questions people ask
- Is Bio-Rad or Bio-Techne growing faster right now
- Bio-Techne grew net sales 5% organically in FY2025 to $1.2 billion, even with a recent 2% organic dip in Q3 FY2026. Bio-Rad's Q1 2026 sales fell 4.2% on a currency-neutral basis, with its process chromatography line down 13%.
- What does the Merck KGaA deal mean for Bio-Techne compared to Bio-Rad
- Merck KGaA agreed to acquire Bio-Techne at $73.00 per share, valuing it at about $11.3 billion enterprise value, a step Bio-Rad has not taken as it remains independent. This gives Bio-Techne a defined near-term path while Bio-Rad continues facing share losses on its own.
- Are Bio-Rad and Bio-Techne at risk from AI replacing their products
- Both companies are rated unlikely to have their core products absorbed by AI, since lab instruments, reagents and antibodies are physical tools rather than software. The bigger risk for both is a larger competitor copying their offerings, which is rated possible for each.
Other comparisons with these companies